StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) stock

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)

Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%

Earnings

enGene Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 8, 2027
Q1 FY2027 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.47
$0.57 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of enGene Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Jan 31, 2027Mar 8, 2027Expected––––
Q4 FY2026ended Oct 31, 2026Nov 12, 2026before the open–––Release
Q3 FY2026ended Jul 31, 2026Sep 8, 2026before the open––-$0.47Release
Q2 FY2026ended Apr 30, 2026Jun 15, 2026before the open––-$0.43Release
Q1 FY2026ended Jan 31, 2026Mar 9, 2026before the open––$0.44Release
Q4 FY2025ended Oct 31, 2025Dec 22, 2025during market hours–––Release
Q3 FY2025ended Jul 31, 2025Sep 11, 2025during market hours––$0.57Release
Q2 FY2025ended Apr 30, 2025Jun 12, 2025before the open–––Release
Q1 FY2025ended Jan 31, 2025Mar 10, 2025during market hours––-$0.48Release
Q4 FY2024ended Oct 31, 2024Dec 19, 2024during market hours–––Release
Q3 FY2024ended Jul 31, 2024Sep 10, 2024during market hours––$0.32Release
Q2 FY2024ended Apr 30, 2024Jun 14, 2024before the open––$0.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

enGene Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When enGene Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases enGene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. Update
  7. Update
  8. Results
  9. Update
  10. Update
  11. Update
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?